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Abstract
Objectives: Isolated intrahepatic recurrence is noted in up to 40% of patients following curative liver
resection for colorectal liver metastases (CLM). The aims of this study were to analyse the outcomes of
repeat hepatectomy for recurrent CLM and to identify factors predicting survival.
Methods: Data for all liver resections for CLM carried out at one centre between 1998 and 2011 were
analysed.
Results: A total of 1027 liver resections were performed for CLM. Of these, 58 were repeat liver
resections performed in 53 patients. Median time intervals were 10.5 months between the primary
resection and first hepatectomy, and 15.4 months between the first and repeat hepatectomies. The
median tumour size was 3.0 cm and the median number of tumours was one. Six patients had a positive
margin (R1) resection following first hepatectomy. There were no perioperative deaths. Significant com-
plications included transient liver dysfunction in one and bile leak in two patients. Rates of 1-, 3- and
5-year overall survival following repeat liver resection were 85%, 61% and 52%, respectively, at a median
follow-up of 23 months. R1 resection at first hepatectomy (P = 0.002), a shorter time interval between the
first and second hepatectomies (P = 0.02) and the presence of extrahepatic disease (P = 0.02) were
associated with significantly worse overall survival.
Conclusions: Repeat resection of CLM is safe and can achieve longterm survival in carefully selected
patients. A preoperative knowledge of poor prognostic factors helps to facilitate better patient selection.
Received 26 November 2012; accepted 7 February 2013
Correspondence
Narendra Battula, Liver Unit, Queen Elizabeth Hospital, Birmingham B15 2TH, UK. Tel: + 44 7743 846045.
Fax: + 44 121 4 141833. E-mail: docnaren@hotmail.com
Introduction
Colorectal cancer (CRC) is the third most common malignancy
and the second most common cause of cancer-related deaths
worldwide.1 Up to 70% of patients with CRC develop either syn-
chronous (15–25%) or metachronous (20–40%) liver metas-
tases.2,3 Despite the recent advances in chemotherapeutic agents,
liver resection remains the only potentially curative treatment for
colorectal liver metastases (CLM).4–8 Reported 5-year overall sur-
vival rates following curative liver resection lie in the range of
35–58%.9–12 However, about two thirds of patients develop
tumour recurrence and the recurrent disease is limited to the liver
in up to 40%.13–16 Advances in surgical techniques and periopera-
tive management have enabled some centres to perform repeat
hepatectomy in selected groups of patients.17–20 Experiences with
repeat resections are limited and the published literature is con-
fined to a few retrospective studies.21–24 The aims of this study were
to analyse the outcomes of repeat hepatectomy performed for
recurrent CLM and to identify factors predicting survival.
Materials and methods
Following approval of the study protocol by the institutional review
board, all patients who underwent surgery for CLM between
January 1998 and January 2011 were identified. Data were collected
retrospectively using the prospectively maintained liver unit data-
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base. Only patients who underwent more than one liver resection
were included in the study. Patients with recurrent liver disease
treated with radiofrequency ablation (RFA) were excluded. Infor-
mation collected included data on patient demographics, clinico-
pathological features of the primary and metastatic tumours,
operative data and postoperative complications in both the single
hepatectomy group and the repeat liver resection group. Rates of 1-,
3- and 5-year overall survival were calculated from the time of first
hepatectomy and were compared with those in the single hepatec-
tomy group. A further analysis was performed to identify factors
influencing survival in the repeat liver resection group.
Preoperative staging included contrast-enhanced, triple-phase
computed tomography and liver-specific magnetic resonance
imaging. All imaging was discussed at a multidisciplinary
meeting. Neoadjuvant chemotherapy was considered in patients
with borderline resectable disease or a clinical risk score of >3.25
The criteria for consideration for repeat liver resection were
similar to those for initial liver resection: patients were required to
show the presence of resectable liver disease, the absence of unre-
sectable extrahepatic disease and the likelihood of an adequate
functional liver remnant following resection. Intermittent inflow
occlusion was used selectively and parenchymal transection was
performed using the Cavitron Ultrasonic Surgical Aspirator
(CUSA; Valleylab™, Covidien, Inc., Boulder, CO, USA) and/or a
harmonic scalpel according to the surgeon’s preference. A thoracic
epidural infusion of bupivacaine and fentanyl was used routinely
to provide postoperative pain relief.
Liver metastases that were diagnosed within 3 months of the
primary tumour were defined as synchronous, whereas those
diagnosed >3 months later were classed as metachronous lesions.26
The extent of liver resection was classified according to the Bris-
bane 2000 Guidelines. Resections involving more than three
Couinaud segments were regarded as major.
Perioperative mortality was defined as death during the same
hospital admission or within 90 days of surgery. Postoperative
complications were graded using the modified Dindo–Clavien
system of classification.27
Patients were followed up by clinical evaluation and measure-
ment of serum carcinoembryonic antigen (CEA) every 3 months
during the first year, every 4 months during the second, every 6
months during the third and annually thereafter until the fifth
anniversary. Computed tomography was performed at 6 and 18
months following surgery and if clinically indicated.
Statistical analysis
Data were analysed using spss Version 17 (SPSS, Inc., Chicago, IL,
USA). Descriptive statistics were presented as percentages or
median values. Non-parametric Mann–Whitney U-tests and chi-
squared tests were used to analyse differences between the single
and repeat hepatectomy groups. Survival was calculated from the
time of both the first and second hepatectomies in the repeat
hepatectomy group and survival analysis was performed accord-
ing to the Kaplan–Meier method. Factors associated with survival
were assessed using the Cox regression test. A P-value of <0.05 was
considered to indicate statistical significance in all tests.
Results
A total of 1027 liver resections were performed for CLM during
the study period. Of these, 58 (6%) represented repeat hepatecto-
mies performed in 53 patients. Five patients underwent a third
liver resection. Single hepatectomy was performed in 916 patients.
The median age at presentation in the repeat hepatectomy group
was 63 years (range: 38–81 years). A total of 29 (55%) of the 53
patients in the repeat hepatectomy group were male.
Primary tumours were staged according to the Dukes classifi-
cation system as stage A in three patients, stage B in 15, stage C in
18 and stage D in 17 patients. Hepatic metastases at index pres-
entation were synchronous in 17 and metachronous in 36
patients. Thirty-one patients received chemotherapy prior to first
liver resection and three received chemotherapy before the repeat
liver resection. The majority of chemotherapy regimens were
5-fluorouracil (5-FU) and oxaliplatin-based The median time
interval between the colectomy and the first hepatectomy was 10.5
months (range: 1.9–65.0 months); median intervals were 15.4
months (range: 4.3–60.1 months) between the first and second
hepatectomies, and 12.2 months (range: 7.7–33.8 months)
between the second and third liver resections.
Operative data
In the 53 patients submitted to repeat liver resection, the first
hepatectomy was major in 25 and minor in 28 cases. The repeat
liver resection was major in 10 and minor in 43 patients. All of the
five third hepatectomies were non-anatomical wedge resections.
Types of liver resection in the repeat hepatectomy group are sum-
marized in Table 1.
Blood products were used in 13 patients during the first hepate-
ctomy and in 10 patients during the repeat procedure. None of the
patients undergoing third hepatectomies required transfusions.
Metastatic tumour characteristics at first
hepatectomy (n = 53)
The median size of the tumour was 3.0 cm (range: 1.0–11.0 cm)
and the median number of lesions was one (range: 1–9). A bilobar
Table 1 Type of liver resection in the repeat hepatectomy group
(n = 53)
Type At first
hepatectomy,
n (%)
At second
hepatectomy,
n (%)
Right hepatectomy 13 (25%) 7 (13%)
Extended right hepatectomy 4 (8%) 2 (4%)
Left hepatectomy 5 (9%) 1 (2%)
Extended left hepatectomy 3 (5%) 0
Left lateral segmentectomy 8 (15%) 2 (4%)
Non-anatomical resections 20 (38%) 41 (77%)
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distribution was noted in 12 patients. One patient showed the
regional spread of tumour to the hilar lymph node. Postoperative
histology showed residual microscopic tumour at the resection
margin (R1 resection) in six patients. No R2 resections were
identified.
Metastatic tumour characteristics at repeat
hepatectomy (n = 53)
The median size of the tumour was 3.0 cm (range: 1.0–7.5 cm)
and the median number of lesions was one (range: 1–3). Four
patients had bilobar disease. Extrahepatic disease was noted in six
patients. Three patients had local diaphragmatic invasion, one had
hilar lymph node metastasis, one had a pre-sacral mass and one
patient had extracapsular tumour infiltration. Final histology
revealed an R1 resection in six specimens. No patients had R2
resection.
Postoperative outcome and survival
No in-hospital deaths occurred after repeat liver resection. Two
patients developed bile leak from the cut surface of the liver and
required percutaneous drainage. One patient developed a chest
infection and another had transient liver dysfunction; both were
treated conservatively.
The median hospital stay was 6 days (range: 4–17 days) and the
median intensive care unit stay was 1 day (range: 1–5 days). None
of the five patients who underwent third hepatectomy had any
significant morbidity.
At a median follow-up of 32 months (range: 5–103 months), 16
patients were found to have died of tumour recurrence. Eleven of
these 16 patients had developed further recurrent metastatic
disease in the liver. Rates of 1-, 3- and 5-year survival calculated
from the date of first hepatectomy were 98%, 83% and 59%,
respectively, with a median survival of 53 months (range: 11–101
months). Rates of 1-, 3- and 5-year survival calculated from the
date of the second liver resection were 85%, 61% and 52%, respec-
tively, with a median survival of 45 months (range: 6–98 months).
The present results are compared with those of previously pub-
lished studies in Table 2.
Comparison with the single hepatectomy group
Patients in the single hepatectomy group (n = 916) and the repeat
liver resection group (n = 53) were comparable with respect to age,
Dukes stage of the primary tumour, the presence of synchronous
liver lesions, the time interval between the resections of the
primary and metastatic lesions, and the size and number of liver
metastases (Table 3). Significantly more major liver resections
were undertaken in the single hepatectomy group compared with
the first repeat resection group. A comparative analysis of intra-
operative blood product requirements and postoperative compli-
cation rates between the two groups revealed no significant
variables. A detailed summary is presented in Table 4.
Rates of 1-, 3- and 5-year overall survival after a single hepate-
ctomy were 95%, 58% and 43%, respectively. The difference in
survival rates between the single hepatectomy and the repeat
hepatectomy groups was not significant. Survival curves are pre-
sented in Fig. 1.
Predictors of survival
Cox regression analysis demonstrated that R1 resection at repeat
hepatectomy (P = 0.002), a shorter time interval between the first
and second hepatectomies (P = 0.02) and the presence of extra-
hepatic disease (P = 0.02) were associated with significantly
poorer survival in patients who underwent repeat hepatectomy.
The details of the analysis are shown in Table 5.
Discussion
A large proportion of patients with CRC with liver metastases
develop tumour recurrence despite surgical treatment with cura-
tive intent. In an estimated 25–30% of these patients, recurrence is
confined to the liver.28 Modern systemic chemotherapy regimens
have achieved a median survival of 20 months in patients with
colorectal metastases. However, data on the efficacy of these treat-
ments in patients with recurrence in the liver following hepatec-
tomy are lacking.22,29 Improvements in surgical technique and
perioperative management have encouraged a few centres to
adopt an aggressive surgical approach in selected patients with
metastatic recurrence.22–24,30
Table 2 Comparison of the present results with those of published studies
Authors (year) Patients,
n
Mortality,
%
Median survival,
months
3-year
survival, %
5-year
survival, %
Fernández-Trigo et al.
(1995)42
(Liver Met Registry)
170 – 34 45% 32%
Adam et al. (2003)43 139 2.5% – 54% 35%
Shaw et al. (2006)24 66 0% 56% 68% 44%
de Jong et al. (2009)44
(multi-institution data)
246 0.4% – – 32.6%
Current studya 53 0% 45 61% 52%
aIn the current study, 3- and 5-year survival rates were calculated from the date of first hepatectomy.
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Repeat liver resection is made challenging by a combination of
factors, such as adhesions from previous surgery, chemotherapy-
induced liver injury and the alterations to the anatomy caused by
regeneration. This has led to perceptions that increased mortality
and morbidity are associated with such resections.31,32
The incidence of repeat liver resection in the present study was
6%; that in a large UK-based study published by Shaw et al. was
7%.24
In the present series, no perioperative mortality occurred fol-
lowing repeat liver surgery. Intraoperative blood product usage,
Table 3 Data on patient demographics and metastatic tumours in the present series
Demographics Single
hepatectomy
(n = 916)
First repeat
hepatectomy
(n = 53)
P-value
Age, years, median (range) 66 (21–87) 63 (38–81) 0.882
Sex, male/female, n 619/297 29/24
Dukes stage of primary tumour, n (%)
A 30 (3%) 3 (6%) 0.471
B 270 (30%) 15 (28%) 0.530
C 377 (41%) 18 (34%) 0.311
D 239 (26%) 17 (32%) 0.334
Synchronous tumour 239 (26%) 17 (32%) 0.334
Time interval, months, median (range)
Primary resection to first hepatectomy 11.5 (0–188.1) 10.5 (1.9–65) 0.396
First to second hepatectomy – 15.4 (4.3–60.1)
Second to third hepatectomy – 12.2 (7.7–33.8)
Size of liver tumour, cm, median (range) 3.5 (1.0–18.5) 3.0 (1.0–11.0) 0.743
Number of liver lesions, n, median (range) 1 (1–9) 1 (1–8) 0.912
Table 4 Intraoperative variables and postoperative complications graded using the Clavien–Dindo classification
Single
hepatectomy
(n = 916)
First liver
resection
(n = 53)
P-value Second live
r resection
(n = 53)
P-value
Type of resection, n (%)
Major 746 (82%) 25 (47%) 0.001 10 (19%) 0.003
Minor 171 (12%) 28 (53%) 43 (81%)
Perioperative transfusions
Blood 0 (0–35 units) 0 (0–18 units) 0.439 0 (0–19 units) 0.818
Fresh frozen plasma 0 (0–22 units) 0 (0–10 units) 0 (0–24 units)
Platelets 0 (0–22 units) 0 0 (0–2 units)
Patients with blood production, % 31% 24% 19%
30-day mortality, n 45 0 0
Liver dysfunctiona, n (%) 9 (2%) [Grade 5: 1] 1 (2%) 0.159 1 (2%) 1.0
Bleeding, n (%) 11 (1%) [Grade 3a: 3] – 1.0 0 1.0
Bile leak, n (%) 55 (6%) [Grade 3a: 17] 4 (7%) [Grade 3a: 1] 0.551 2 (4%) [Grade 3a: 2] 0.628
Pulmonary complications, n (%) 52 (6%) [Grade 3a: 2; Grade 4: 4] 2 (4%) 0.768 1 (2%) 1.0
AF/dysrhythmia, n (%) 40 (4%) – 0.061 – 1.0
Abdominal collections, n (%) 3 (<1%) [Grade 3a: 2] – 0.153 – 1.0
Wound infection, n (%) 17 (2%) – 0.610 – 1.0
Wound dehiscence, n (%) 3 (<1%) [Grade 3b: 2] – 0.151 – 1.0
aPostoperative liver dysfunction was defined using the 50–50 criteria (serum prothrombin time <50% of normal, bilirubin >50 mmol/l on postoperative
day 5.45
Significant complications requiring surgical, endoscopic or radiological intervention and life-threatening complications are shown in parentheses.
AF, atrial fibrillation.
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postoperative morbidity and length of hospital stay were compa-
rable between the repeat and single hepatectomy groups. However,
the majority of repeat hepatectomies in the study group were
minor, as they were in other published series.31–35 Over the years, the
unit at which this study was conducted has adopted a strict tech-
nique for first hepatectomy that involves the mobilizing of only the
lobes with target lesions, minimal retrohepatic dissection and the
use of parenchyma-preserving resection when possible. This
approach is intended to minimize adhesions and perihepatic fibro-
sis and thus to facilitate any future repeat hepatectomies.
Numbers at risk: 
Repeat hepatectomy- 
       25      7             0         0 
Single hepatectomy 
      436               65                  5                  0 
Case processing summary
Repeat hepatectomy = 1 
Single hepatectomy = 2
Patients, 
n
Events (death), 
n
Censored 
n %
1.00 53 25 28 52.8%
2.00 916 436 480 52.4%
Overall 969 461 508 52.4%
Figure 1 Kaplan–Meier curves showing survival in the single hepatectomy and repeat hepatectomy groups
Table 5 Cox regression analysis: factors predicting survival in the repeat liver resection group
Factors P-value HR (95% CI)
Time interval between first and second resections 0.021 1.095 (3.37–5.14)
Type of resection (major versus minor) 0.783 1.747 (0.15–2.50)
Tumour distribution (unilateral versus bilateral) 0.443 0.629 (0.46–12.40)
R1 resection at second hepatectomy 0.002 11.054 (2.90–3.70)
Presence of extrahepatic disease 0.025 1.847 (1.60–2.50)
Age 0.637 0.736
HR, hazard ratio; 95% CI, 95% confidence interval.
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Five-year survival in patients who underwent a repeat hepate-
ctomy was 59% in the present study; this was slightly better than
the 43% achieved in patients undergoing single hepatectomy. The
survival benefit to be derived from repeat liver resection is also
indicated by the results of other studies reported in the literature,
which quote 5-year survival rates ranging from 26% to 44%.24 The
enhanced survival noted in the present group is likely to relate to
the fact that this was a highly selected patient population with
favourable tumour biology.
Complete tumour clearance at index hepatectomy is crucial for
a good prognosis.36 Accurate preoperative staging to identify all
tumour nodules is a key factor in achieving clearance. Early
tumour recurrence usually reflects unidentified metastatic disease
or a positive microscopic resection margin. The Cox regression
analysis in the present study showed that early recurrence (or a
shorter time interval between the first and second hepatectomies)
was associated with a poor prognosis. An R1 resection and the
presence of extrahepatic disease were also associated with a poor
prognosis. Aggressive surveillance to identify residual disease and
early recurrence could potentially extend the benefits of repeat
hepatectomy to a wider population and thus improve outcomes.
Neoadjuvant chemotherapy may be considered in patients
affected by poor prognostic factors.37
The role of RFA as a primary treatment modality for recurrent
CLM is currently unclear. It has been shown to confer an accept-
able survival benefit in patients with CLM: for example, Solbiati
et al. demonstrated a 3-year survival rate of 46% in patients
treated with RFA.38 Although the results were encouraging, the
role of RFA in recurrent CLM has not been thoroughly studied.39
Published studies have tended to include patients who were not fit
for surgical intervention and therefore it is not possible to
compare the short- and longterm outcomes of RFA and surgery,
respectively, for recurrent CLM. Further, studies have also
reported local intrahepatic recurrence in up to 40% of patients
following ablation treatments.40 At the present centre, the low
morbidity and good longterm survival rates associated with
surgery have restricted the use of RFA to its administration in
combination with surgery or as a second-line treatment in
patients who are unfit for surgery.
A small proportion of patients (10%) with recurrent CLM iso-
lated to the liver are amenable to repeat liver resection. Published
experience in repeat hepatectomy for recurrent CLM is derived
from small retrospective studies that support the role of repeat
hepatectomy as a curative treatment in carefully selected
patients.41 The present results concur with current opinion. The
roles of more conservative modalities, such as chemotherapy or
local ablative treatments (alone or in combination), should be
addressed in randomized controlled trials.
In conclusion, repeat hepatectomy is safe and provides survival
outcomes comparable with those of single hepatectomy in
selected patients with recurrent CLM. Both technical and onco-
logical factors should be considered at patient selection. The pres-
ence of a positive resection margin, extrahepatic disease and a
shorter time interval between the first and repeat hepatectomies
are associated with a significantly poorer outcome.
Conflicts of interest
None declared.
References
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. (2010)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int
J Cancer 127:2893–2917.
2. Stangl R, Altendorf-Hofmann A, Charnley RM. (1994) Factors influencing
the natural history of colorectal liver metastases. Lancet 343:1405–1410.
3. Scheele J, Stangl R, Altendorf-Hofmann A. (1990) Hepatic metastases
from colorectal cancer: impact of surgical resection on the natural history.
Br J Surg 77:1241–1246.
4. Altendorf-Hofmann A, Scheele J. (2003) A critical review of the major
indicators of prognosis after resection of hepatic metastases from color-
ectal carcinoma. Surg Oncol Clin N Am 12:165–192.
5. Pawlik T, Schulick R, Choti M. (2008) Expanding criteria for resectability
of colorectal liver metastases. Oncologist 13:51–64.
6. Khatri VP, Petrelli NJ, Belghiti J. (2005) Extending the frontiers of surgical
therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol
23:8490–8499.
7. Chuanq SC, Su YC, Lu CY, Hsu HT, Sun LC, Shih YL et al. (2011) Risk
factors for the development of metachronous liver metastasis in color-
ectal cancer patients after curative resection. World J Surg 35:424–429.
8. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. (1999) Clinical
score for predicting recurrence after resection for metastatic colorectal
cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–321.
9. Abdalla EK, Vauthey JN, Ellis LM. (2004) Recurrence and outcomes
following hepatic resection, radiofrequency ablation, and combined
resection/ablation for colorectal liver metastases. Ann Surg 239:818–827.
10. Sharma S, Camci C, Jabbour N. (2008) Management of hepatic metas-
tasis from colorectal cancers: an update. J Hepatobiliary Pancreat Surg
15:570–580.
11. Jamison RL, Donohue JH, Nagorney DM. (1997) Hepatic resection for
metastatic colorectal cancer results in cure in some patients. Arch Surg
132:505–510.
12. Hughes KS, Simon R, Songhorabotdi S, Adson MA, Ilstrup DM, Fortner
JG. (1986) Resection of the liver for colorectal carcinoma metastases: a
multi-institutional study of patterns of recurrence. Surgery 100:278–284.
13. Sa Cunha A, Laurent C, Rault A, Couderc P, Rullier E, Saric J. (2007) A
second liver resection due to recurrent colorectal liver metastases. Arch
Surg 142:1144–1149.
14. Yamashita Y, Adachi E, Toh Y, Ohgaki K, Ikeda O, Oki E et al. (2011) Risk
factors for early recurrence after curative hepatectomy for colorectal liver
metastases. Surg Today 41:526–532.
15. Steele G Jr, Bleday R, Mayer RJ, Lindblad A, Petreli N, Weaver D. (1991)
A prospective evaluation of hepatic resection for colorectal carcinoma
metastases to the liver: Gastrointestinal Tumour Study Group Protocol
6584. J Clin Oncol 9:1105–1112.
16. Ohlsson B, Stenram U, Tranberg KG. (1998) Resection of colorectal liver
metastases: 25-year experience. World J Surg 22:268–277.
17. Brachet D, Lermite E, Rouquette A, Lrimier G, Hamy A, Arnaud JP. (2009)
Prognostic factors of survival in repeat liver resection for recurrent color-
ectal metastases: review of sixty-two cases treated at a single institution.
Dis Colon Rectum 52:475–483.
162 HPB
HPB 2014, 16, 157–163 © 2013 International Hepato-Pancreato-Biliary Association
18. Yan T, Sim J, Black D, Niu R, Morris D. (2007) Systematic review on safety
and efficacy of repeat hepatectomy for recurrent liver metastases from
colorectal carcinoma. Ann Surg Oncol 14:2069–2077.
19. Que FG, Nagorney DM. (1994) Resection of ‘recurrent’ colorectal metas-
tases to the liver. Br J Surg 81:255–258.
20. Fowler WC, Hoffman JP, Eisenberg BL. (1993) Redo hepatic resection for
metastatic colorectal carcinoma. World J Surg 17:658–661.
21. Petrowsky H, Gonen M, Jarnagin W. (2002) Second liver resections are
safe and effective treatment for recurrent hepatic metastases from color-
ectal cancer: a bi-institutional analysis. Ann Surg 235:863–871.
22. Riesener KP, Kasperk R, Winkeltau G, Schumpelick V. (1996) Repeat
resection of recurrent hepatic metastases – improvement in prognosis?
Eur J Surg 162:709–715.
23. Nordlinger B, Vaillant JC, Guiguet M. (1994) Survival benefit of repeat liver
resections for recurrent colorectal metastases: 143 cases. Association
Française de Chirurgie. J Clin Oncol 12:1491–1496.
24. Shaw IM, Rees M, Welsh FK, Bygrave S, John TG. (2006) Repeat hepatic
resection for recurrent colorectal liver metastases is associated with
favourable longterm survival. Br J Surg 93:457–464.
25. Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik T, Choti M. (2006)
Selection of patients for hepatic colorectal metastases: a Consensus
Statement. Ann Surg Oncol 13:1261–1268.
26. NgWW, Cheung YS,Wong J, Lee KF, Lai PB. (2009) A preliminary analysis
of combined liver resection with new chemotherapy for synchronous and
metachronous colorectal liver metastasis. Asian J Surg 32:189–197.
27. Dindo D, Demartines N, Clavien PA. (2004) Classification of surgical
complications. A new proposal with evaluation in a cohort of 6336
patients and results of a survey. Ann Surg 240:205–213.
28. Chan KM, Chiang JM, Lee CF, Yu MC, Lee WC, Chen JS et al. (2011)
Outcomes of resection for colorectal cancer hepatic metastases stratified
by evolving eras of treatment. World J Surg Oncol 9:174.
29. Ishiguro S, Akasu T, Fujimoto Y. (2006) Second hepatectomy for recur-
rent colorectal liver metastasis: analysis of preoperative prognostic
factors. Ann Surg Oncol 13:1579–1587.
30. Pessaux P, Lermite E, Brehant O, Tuech JJ, Lorimier G, Arnaud JP. (2006)
Repeat hepatectomy for recurrent colorectal liver metastases. J Surg
Oncol 93:1–7.
31. Jakab F, Mersich T. (2010) Repeat resection of the liver – a challenge in
modern oncologic surgery. Magy Seb 63:3–8.
32. Aramaki M, Kawano K, Kai T, Sasaki A, Ohno T, Yoshida T et al. (2000)
Postoperative complications of repeat hepatectomy for liver metastasis
from colorectal carcinoma. Hepatogastroenterology 47:478–480.
33. Suzuki S, Sakaguchi T, Yokoi Y. (2001) Impact of repeat hepatectomy on
recurrent colorectal liver metastases. Surgery 129:421–428.
34. Zacharias T, Jaeck D, Oussoultzoglou E. (2004) First and repeat resection
of colorectal liver metastasis in elderly patients. Ann Surg 240:858–865.
35. Ruiz-Tovar J, Lopez Hervas P. (2010) Repeated liver resection for recur-
rence of colorectal cancer metastases. Clin Transl Oncol 12:634–638.
36. Mise Y, Imamura H, Hashimoto T, Seyama Y, Aoki T, Hasegawa K et al.
(2010) Cohort study of the survival benefit of resection for recurrent
hepatic and/or pulmonary metastases after primary hepatectomy for
colorectal metastases. Ann Surg 251:902–909.
37. Hebbar M, Pruvot FR, Romano O, Triboulet JP, de Gramont A. (2009)
Integration of neoadjuvant and adjuvant chemotherapy in patients with
resectable liver metastases from colorectal cancer. Cancer Treat Rev
35:668–675.
38. Solbiati L, Livraghi T, Goldberg SN, Ierace T, Meloni F, Dellanoce M et al.
(2001) Percutaneous radiofrequency ablation of hepatic metastases from
colorectal cancer: longterm results in 117 patients. Radiology 221:159–
166.
39. Elias D, De Baere T, Smayra T, Ouellet JF, Roche A, Lasser P. (2002)
Percutaneous radiofrequency thermoablation as an alternative to surgery
for treatment of liver tumour recurrence after hepatectomy. Br J Surg
89:752–756.
40. Tsai S, Pawlik TM. (2009) Outcomes of ablation versus resection for
colorectal liver metastases: are we comparing apples with oranges? Ann
Surg Oncol 16:2422–2428.
41. de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD et al.
(2009) Rates and patterns of recurrence following curative intent surgery
for colorectal liver metastasis: an international multi-institutional analysis
of 1669 patients. Ann Surg 250:440–448.
42. Fernández-Trigo V, Shamsa F, Sugarbaker PH. (1995) Repeat liver resec-
tions from colorectal metastasis. Repeat Hepatic Metastases Registry.
Surgery 117:296–304.
43. Adam R, Pascal G, Azoulay D, Tanaka K, Castaing D, Bismuth H. (2003)
Liver resection for colorectal metastases: the third hepatectomy. Ann
Surg 238:871–883.
44. de Jong MC, Mayo SC, Pulitano C, Lanella S, Ribero D, Strub J et al.
(2009) Repeat curative intent liver surgery is safe and effective for recur-
rent colorectal liver metastasis: results from an international multi-
institutional analysis. J Gastrointest Surg 13:2141–2151.
45. Balzan S, Belghiti J, Farges O, Ogata S, Sauvanet A, Delefosse D et al.
(2005) The ‘50–50 criteria’ on postoperative day 5: an accurate predictor
of liver failure and death after hepatectomy. Ann Surg 242:824–828.
HPB 163
HPB 2014, 16, 157–163 © 2013 International Hepato-Pancreato-Biliary Association
